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Background Breast cancer is considered as a hormone driven cancer [1]. The majority of breast cancers are slow growing and convey good clinical outcome [2], however a subset acquires an aggressive phenotype in terms of molecular, genotypic, and phenotypic features resulting in multiple subtypes and 
classifications of breast cancer [3,4]. Historically, breast cancer 
has been classified as ER (oestrogen receptor) positive or 
negative based on expression or lack of expression of ER or 
PR (progesterone receptor). Based on cell-type and molecular signature, molecular subtypes have emerged as into luminal A, 
luminal B, Her2 (human epidermal growth factor receptor 2) 
like and basal-like or triple negative breast cancer (TNBC) [3]. The luminal subtypes have good prognosis and usually 
treated with ER targeted therapy. Her2 like is treated by Her2-
targeting antibodies Trastuzumab with significant improvement 
in survival [5]. TNBC exhibit aggressive features and associated 
with increased mortality. With the exception of EGFR targeted therapy [6], to date there is no targeted treatment for this group. 
 Therefore, there is an increasing need to identify a biomarker as 
a therapeutic target for those patients. Androgen receptor (AR) 
(a steroid hormone nuclear receptor) has more recently emerged 
as a possible biomarker for cancer treatment in ER positive 
patients that fail endocrine therapy and in TNBC patients [7]. 
AR is even more widely expressed in breast cancer than ER 
or PR, with more than 70% invasive cells expressing AR [8]. The 
magnitude and direction of association between AR expression 
and clinical outcome in both ER-positive and ER-negative breast 
cancer is still unclear. In addition, gene expression profiling of 
breast cancer suggests a significant functional role for AR in 
multiple subtypes of breast cancer [4,9]. Preclinical studies also have demonstrated that androgens can lead to proliferation 
of AR-expressing breast cancer cell lines and promote tumour formation in animal models [10]. The proposed mechanism 
for these findings is that that signalling through AR replaces 
oestrogen-dependent signalling as the major determinant of 
steroid-related gene expression. This signalling can exert a 
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stimulatory effect through the androgen responsive element, thereby stimulating transcription of steroid responsive genes [11].Clinical data have also shown contradictory results on the 
prognostic power of AR in breast cancer [12-18]. Therefore, the role of androgen and androgen receptor pathway in breast 
cancer growth and progression remain undefined. In addition, it is increasingly apparent that cancer progression and outcomes in breast cancer are not solely dependent on characteristics of the tumour but also on the interactions between the tumour 
and the host [19]. Components of tumour microenvironment 
including tumour inflammatory infiltrate and tumour budding are now increasingly recognised that they play a key role in cancer progression and survival [20,21]. Therefore, the aim of this study was to examine the relationship between androgen receptor, clinicopathological characteristics, and components of the tumour microenvironments outcome across the molecular subtypes of patients with invasive ductal breast cancer.
Materials and Methods
Patient Cohort Characteristics Patients presenting with invasive ductal breast cancer 
at Glasgow Royal Infirmary, Western Infirmary and Stobhill 
Hospital between 1995 and 1998 with formalin-fixed paraffin embedded blocks of the primary tumour available for evaluation 
were studied (n =850). The study was approved by the Research Ethics Committee of the West Glasgow University Hospitals 
NHS Trust. Clinicopathological data including age, tumour size, tumour grade, lymph node status, type of surgery and use of 
adjuvant treatment (chemotherapy, hormonal based therapy 
and/ or radiotherapy) were retrieved from the routine reports. 
Tumour grade was assigned according to the Nottingham 
Grading System. ER and PR status were assessed on tissue 
microarrays (TMAs) using immunohistochemistry (IHC) with 
Dako (Glostrup, Denmark) ER antibody and Leica (Wetzlar, 
Germany) PR antibody. Her2 status were assessed visually using TMAs as previously described [22].
Section haematoxylin and eosin (H&E) slides for the 752 
patients were used to score local inflammatory infiltrate 
according to Klintrup-Makinen (KM) criteria. KM scoring of 
slides was carried out as previously described. Briefly, tumours 
were scored on four-point scores based on appearances at the 
tumour invasive margin. A score of 0 signified that there were 
no inflammatory cells at tumour’s invasive margin; score 1 
indicated a mild and patchy inflammatory cell; score 2 denoted 
a prominent band-like inflammatory reaction at the invasive 
margin; and score 3 revealed a florid cup-like inflammatory 
infiltrate at the invasive edge [23]. 
Full-section H&E slides were also used to score the tumour 
stroma percentage (TSP) [24] and tumour budding [25] as 
previously reported. Briefly, at 5x magnification, an area representative of the tumour invasive margin was selected, and 
then a single field of 10x magnification was examined, ensuring that tumour cells were present at all four sides of the image and the area of stroma was calculated as a percentage. Tumour 
budding was evaluated as clusters of 1-5 cancer cells within the tumour microenvironment bud. 
The molecular subtypes were defined as follows: Luminal 
A: oestrogen (ER) and/or progesterone receptor (PR) positive, 
Her-2 negative or low proliferative index (< 15%); Luminal B: 
hormone receptor positive, Her- 2 positive or high proliferative 
index (> 15%); Her-2 subtype: Her-2 positive and hormone receptor negative, any proliferative index; and triple negative: 
Her-2 negative, hormone receptor negative, any proliferative index. 
Immunohistochemistry Optimisation of the antibody utilised was demonstrated using a single band of appropriate size, on a western blot and immunohistochemistry was performed. Antibody validation 
for AR was carried out as previously described [26]. IHC was 
conducted in triplicate on tissue microarrays (TMAs). Slides were dewaxed in xylene and rehydrated through graded alcohol. 
For total AR, antigen retrieval was performed under pressure in 
a solution of Tris-EDTA buffer (10 mM Trizma Base, 0.25 mM 
EDTA), 96°C for 5min. Endogenous peroxidase were blocked 
with 3% H2O2. Sections were further blocked using 5% horse 
serum in Tris-buffered saline for 30 mins. Samples were then 
incubated overnight in a dark box at 4oC in 1:300 primary 
monoclonal antibody directed against AR (Reference M3562; 
Lot 10114412; Dako UK Ltd. Monoclonal Mouse; Anti-Human; 
Androgen Receptor; Clone AR441; Isotope IgG1, kappa), diluted 
using DAKO antibody diluent (Reference S0809; Lot 10121673; 
Dako North America, Inc. 6392 Via Real Carpinteria, CA, 93013 
USA). Bound antibody complex was visualised using EnVision 
plus kit (Dako UK Ltd.) followed by 3,3-diaminobenzidine 
tetrahydrochloride (DAB, Dako UK Ltd.). Tissue samples were counterstained with haematoxylin and blued with Scots Tap Water Substitute, dehydrated through graded alcohol and xylene 
and mounted with Di-N-Butyl Phthalate in xylene (DPX).
Scoring 
TMAs were scanned using the Hamamatsu Nano Zoomer 
(Welwyn Gardens City, Hertfordshire, UK) at x 20 magnification, and visualisation was carried out using Slide path Digital 
Image Hub, version 4.0.1 (Leica Biosystems, UK). The weighted 
histoscore method (H-score system) was used to blind score 
the tissue staining intensity of AR by 2 independent observers blinded to the clinical data. Histoscores were calculated from 
the sum of (1 X % cells staining weakly positive) + (2 X % cells 
staining moderately positive) + (3 X % cells staining strongly 
positive) with a maximum of 300. Each core has been scored 
and rescored by the researcher and 10% of scoring verified by 
an independent observer to ensure accuracy. The inter-class 
correlation coefficient (ICC) is calculated to confirm consistency 
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between observers, where the mean scores of the two observers will be used for analysis.
Statistical Analysis 
Only patients with a score for AR were included in the 
analysis (n = 752). Cut-off values for high or low protein expression were determined by the median of the average values 
of the intensity of staining. 10% cut-off was used in this paper analysis. The relationships between variables were assessed 
using contingency table analysis with the X2 test for linear trend. 
Correlations coefficients were analysed using a Spearman’s rho. Kaplan– Meier curves with log rank analysis was used to 
examine the effect of protein expression on cancer-specific 
survival (CSS). Univariate survival analysis was performed using 
Cox proportional hazards regression. Variables with P-value of 
< 0.05 were entered a multivariable model using a backwards conditional method for all patients and triple negative patients. 
All statistical analyses were two-sided, and significance defined 
as P-value < 0.05. All statistical analysis was performed using the 
SPSS software version 22 (IBM SPSS, Chicago, IL, USA). 
Results 
Table 1: The relationship between clinicopathological characteristics and AR status (full cohort).
N (%) AR –ve n=293(39%)
AR +ve 
n=459(61%) P-value
Age (≤50/ >50 years) 224(30%)/528(70%) 96/197 128/331 0.154
Size (≤20/ 21-50/ >50 mm) 241(56%)/289(38%)/41(6%) 165/115/13 256/174/28 0.640
Grade (I / II / III) 132(18%)/332(44%)/287(38%) 36/112/114 96/220/143 <0.001
Lymph node (negative/positive) 417(56%)/323(43%) 161/129 256/194 0.714
ER status (no/yes) 251(33%)/499(66%) 158/135 93/364 <0.001
PR status (no/yes) 402(54%)/348(46%) 203/90 199/258 <0.001
Her2 status (no/ yes) 612(81%)/126(17%) 232/52 380/74 0.480
Molecular subtypes (luminal A/luminal B/ Her2 like/
TNBC)
330(44%)/167(22%)/72(10%)/
160(21%) 83/50/38/110 247/117/34/50 <0.001
Tumour necrosis (low/high) 372(49%)/358(48%) 117/172 225/186 <0.001
Klintrup–Mäkinen grade (no/any) 120(16%)/610(81%) 21/265 99/345 <0.001
Tumour-stroma percentage (low/high) 511(68%)/224(30%) 200/89 311/135 0.880
Tumour budding (low/high) 493(66%)/242(32%) 214/75 279/167 0.001
Endocrine therapy (none/tamoxifen/ATAC) 130(17%)/459(61%)/29(4%) 81/168/0 49/291/29 <0.001
Adjuvant chemotherapy (no/yes) 440(59%)/310(41%) 136/155 304/155 <0.001
Adjuvant radiotherapy (no/yes) 397(53%)/353(47%) 155/136 242/217 0.885
Survival (alive/cancer death/non cancer death) 424(56%)/165(22%)/144(19%) 165/61/58 259/104/86 0.649
Luminal A (n=330) n=83(25%) n=247(75%)
Tumour budding (low/high) 58/23 135/101 0.022
Endocrine therapy (none/tamoxifen/ATAC) 8/72/0 18/178/17 0.057
Adjuvant chemotherapy (no/ yes) 51/31 184/63 0.033
Luminal B (n=167) n=50(30%) n=117(70%)
Necrosis (low/high) 20/29 65/50 0.066
Klintrup–Mäkinen grade (no/any) 3/46 33/84 0.002
Her-2 like (n=72) n=38(53%) n=34(47%)
Tumour budding (low/high) 24/14 29/5 0.035
Triple negative (n=160) n=110(69%) n=50(31%)
Tumour budding (low/high) 90/19 33/16 0.034
Adjuvant chemotherapy (no/yes) 35/74 24/26 0.055
In molecular subtypes only, variables with association are shown.
Only patients with staining for AR were included in the 
analysis (n = 752). Table 1 summarises clinicopathological 
characteristics of patients. Most of the patients (70%) were 
above 50 years old, had small tumour size ≤ 20 mm (56%), had 
grade II and III tumours (82%) and no involved lymph nodes 
(56%). ER positive tumours (66%), PR negative tumours (53%) 
and HER2 negative tumours (81%) formed most tumours. 81% 
of patients had positive Klintrup-Makinen (KM) grade, 32% 
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had high tumour budding and 30% had high TSP. 459(61%) of 
the patients received endocrine therapy, 29 (4%) of patients 
received aromatase inhibitor treatment, and 310 (41%) of patients received adjuvant chemotherapy. The median survival 
was 149 months with 165 deaths from breast cancer. Number of 
events was 46 in luminal A, 30 in luminal B, 24 in Her2 like and 
46 in TNBC. 
AR expression at cut-off 10% were identified in 459 (61%) 
of patients. The relationship between AR and clinicopathological 
characteristics is presented in Table 1. AR expression was 
significantly associated with lower grade (p<0.001), ER/
PR+ve tumours (p < 0.001), molecular subtype (p<0.001), 
lower necrosis (p<0.001), weak Klintrup-Makinen (KM) grade 
(p<0.001) and increased tumour budding (p=0.001). AR was 
also significantly associated with increased endocrine treatment 
and reduced chemotherapy treatment (p < 0.001). 
Table 2: The relationship between clinicopathological characteristics and cancer specific survival in patients with AR+ve group (n=459).
Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Age (<50/ >50 years) 1.19(0.63-2.27) 0.589
Size (≤20/ 21-50/ >50 mm) 1.85(1.09-3.13) 0.022 1.81(1.33-2.45) <0.001
Grade (I / II / III) 1.89(1.16-3.08) 0.010 1.69(1.20-2.36) 0.003
Involved lymph node (no/yes) 2.58(1.39-4.79) 0.003 1.89(1.22-2.93) 0.004
ER receptor status (no/yes) 0.44(0.24-0.83) 0.010 0.836
PR receptor status (no/yes) 0.46(0.22-0.94) 0.035 0.130
Her2 status (no/yes) 1.73(0.18-4.19) 0.325
Tumour necrosis (low/high) 4.51(2.02-10.09) <0.001 2.056(1.31-3.22) 0.002
Klintrup–Mäkinen grade (no/any) 1.43(0.79-2.57) 0.232
Tumour stroma percentage (low/high) 2.06(1.15-3.69) 0.115
Tumour budding (low/high) 2.20(1.23-3.94) 0.007 1.95(1.28-2.98) 0.002
Endocrine therapy (none/tamoxifen/ATAC) 2.38(1.15-4.94) 0.520
Adjuvant chemotherapy (no/yes) 1.93(1.36-2.84) 0.001 0.160
Table 3 : The relationship between clinicopathological characteristics and cancer specific survival in patients with AR-ve group (n=293).
Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Age (<50/ >50 years) 1.34(0.53-3.41) 0.589
Size (≤20/ 21-50/ >50 mm) 1.66(1.10-2.50) 0.015 0.154
Grade (I / II / III) 1. 96(1.26-3.04) 0.003 0.180
Involved lymph node (no/yes) 3.24(1.88-5.57) 0.003 2.97(1.70-5.19) <0.001
ER receptor status (no/yes) 0.51(0.30-0.87) 0.014 0.157
PR receptor status (no/yes) 0.54(0.29-0.99) 0.048 0.117
Her2 status (no/yes) 1.81(1.02-3.21) 0.043 0.606
Tumour necrosis (low/high) 3.41(1.77-6.54) <0.001 3.21(1.66-6.17) <0.001
Klintrup–Mäkinen grade (no/any) 0.73(0.29-1.82) 0.232
Tumour stroma percentage (low/high) 2.42(1.46-3.99) 0.001 2.10(1.26-3.51) <0.001
Tumour budding (low/high) 1.64(0.97-2.79) 0.064 0.273
Endocrine therapy (none/tamoxifen/ATAC) 0.76(0.43-1.35) 0.353
Adjuvant chemotherapy (no/yes) 1.85(1.08-3.17) 0.023 0.703
Patients were then stratified according to AR status into 
AR +ve and AR -ve groups and the relationship between 
clinicopathological characteristics and cancer specific survival 
were examined in both groups (Tables 2 & 3). In AR +ve patients, 
tumour size (p<0.001), grade (P=0.003) and lymph node 
(P=0.004) were independently associated with CSS as well as 
tumour necrosis and budding (both P=0.002). The hazard ratio 
(1.95) of tumour budding was stronger than that for size (1.81), 
grade (1.69), and lymph node (1.89) the most useful pathological 
variables for breast cancer prognosis in AR + ve group. In AR –
ve patients, lymph node (p<0.001), tumour necrosis (p<0.001) 
and tumour stroma percentage (p<0.001) were independent prognostic factors of poor CSS. 
As AR was associated with molecular subtype Table 1, 
patients were stratified into molecular subtypes, luminal 
A (n=330), luminal B (n=167), Her2 like (n=72) and TNBC 
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(n=160). In luminal A tumours, AR was significantly associated 
with increased tumour budding (p= 0.022) and reduced adjuvant 
chemotherapy (p = 0.033). In luminal B, AR was significantly 
associated with weak Klintrup-Makinen (KM) grade (p =0.002). 
AR was significantly associated with reduced tumour budding 
in Her2 like (p =0.035), and increased tumour budding in TNBC 
(p =0.034). 
The relationship Between AR and survival outcome 
Kaplan–Meier survival curves show that AR expression in the 
whole cohort was not associated with CSS (P=0.713) Figure 1. 
AR was significantly associated with CSS in luminal A (P=0.028) 
and TNBC (P=0.013) Figure 2. In contrast, in patients with luminal B and Her2 like tumours the correlation was lost, and 
no associations were seen (P=0.916 and P=0.195 respectively). Therefore, further survival analysis was not carried out for those 
subtypes. In univariate analysis for luminal A, and for TNBC AR 
was significantly associated with CSS (P=0.028 and P=0.013 
respectively) (Tables 4 & 5). In multivariate analysis for luminal 
A, AR (P=0.046), size (P=0.005), grade (P=0.028) and lymph 
node (P=0.013) were independent prognostic factors (Table 4). 
In multivariate analysis for TNBC, size (p<0.001), lymph node 
(P=0.001), tumour necrosis (P=0.007), and tumour budding 
(P=0.008) were independent prognostic factors. However, AR does not appear to be independently prognostic in these patients 
(p=0. 357) (Table 5). 
Figure 1: Kaplan-Meier survival curves (Log rank) of cancer 
specific survival) in all patients P=0.713
Figure 2: Kaplan-Meier survival curves (Log rank) of cancer specific survival in different molecular subtypes (A) Luminal A P=0.028 (B) 
Luminal B P=0.916 (C) Her2 like P=0.195 (D) Triple negative P=0.013.
Discussion 
The results of present study have shown that AR expression in breast cancer was associated with tumour budding and poor 
survival outcome particularly in TNBC. However, the prognostic 
of AR was not independent of the prognostic value of tumour 
budding. This may suggest that AR was a regulator of tumour budding and therefore a potential therapeutic target in patients 
with TNBC patients. In this study and with a cut-off value of 
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10%, AR was positive in more than 60% of patients (> 70% in 
luminal A and B, 47% for Her2 like and 31% for TNBC). This 
observation was consistent with previous reports [8,13,17,27-
29]. The basis of phenotypic and survival effects was subtype-
dependent. In TNBC we observed that increased expression of AR 
was significantly associated with reduced CSS. Previous reports 
also have shown that AR expression in ER negative tumours 
and TNBC were associated with higher nuclear grade, increased 
risk of mortality and reduced survival [15-17,29,30] consistent 
with our results. The unfavourable association between AR 
expression and outcome in TNBC may be due to AR expression 
increasing the dissociation of tumour cells via up-regulation of 
tumour budding. In AR +ve tumours, tumour budding was an 
independent prognostic factor of CSS (Table 2) compared with 
that of AR –ve group (Table 3). 
Table 4: The relationship between clinicopathological characteristics and cancer specific survival in Luminal A (n=303).Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Age (<50/ >50 years) 1.51(0.72-3.17) 0.279
Size (≤20/ 21-50/ >50 mm) 2.17(1.43-3.30) <0.001 1.93(1.02-6.59) 0.005
Grade (I / II / III) 1.94(1.22-3.06) 0.005 1.76(1.06-2.92) 0.028
Involved lymph node (no/yes) 3.03(1.63-5.64) <0.001 2.27(1.19-4.30) 0.013
Androgen receptor (low/high) 2.72(1.07-6.89) 0.028 2.58(1.02-6.59) 0.046
Tumour necrosis (low/high) 2.16(1.19-3.90) 0.011 0.158
Klintrup–Mäkinen grade (week/strong) 0.85(0.43-1.63) 0.644
Tumour stroma percentage (low/high) 1.74(0.96-3.15) 0.067 0.194
Tumour budding (low/high) 1.23(0.68-2.21) 0.494
Endocrine therapy (none/tamoxifen/ATAC) 0.63(0.80-1.54) 0.667
Adjuvant chemotherapy (no/yes) 1.82(1.02-3.24)) 0.044 0.803
It is of interest that, in this study, AR was consistently associated with increased tumour budding in all patients and 
different subgroups. To best of our knowledge this is the first 
breast cancer study to report an association between AR and tumour budding in clinical settings. With increased appreciation of the importance of the tumour budding in cancer progression 
[25,31] this positive relationship between AR and budding 
might provide some clarification of the poor outcome that 
TNBC patients’ experience. It was also interesting that tumour budding was shown to be an independent prognostic factor in 
TNBC, suggesting a link between AR stimulation and epithelial 
mesenchymal transition (EMT) the molecular form of tumour 
budding [31] potentially via AR up-regulation of ZEB2 [32] and 
suppression of E-cadherin [33,34]. Also, AR may have EMT-promoting effects even independently of EMT transcription 
factors [35].
Table 5: The relationship between clinicopathological characteristics and cancer specific survival in TNBC (n=160).Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Age (<50/ >50 years) 1.51(0.72-3.17) 0.279
Size (≤20/ 21-50/ >50 mm) 3.54(2.11-5.95) <0.001 2.66(1.55-4.58) <0.001
Grade (I / II / III) 0.86(1.07-0.52) 0.858
Involved lymph node (no/yes) 4.53(2.34-8.76) <0.001 3.29(1.67-6.56) 0.001
Androgen receptor (low/high) 2.06(1.15-3.07) 0.013 0.357
Tumour necrosis (low/high) 6.03(1.86-19.46) 0.003 5.21(1.58-17.12) 0.007
Klintrup–Mäkinen grade (week/strong) 0.67(0.34-1.45) 0.335
Tumour stroma percentage (low/high) 2.05(1.12-3.78) 0.021 0.101
Tumour budding (low/high) 2.84(1.56-5.16) 0.001 2.42(1.25-4.68) 0.008
Endocrine therapy (none/tamoxifen/ATAC) 0.85(0.40-1.17) 0.667
Adjuvant chemotherapy (no/yes) 1.12(0.60-2.07) 0.714
Because TNBC have relatively aggressive tumour biology and limited treatment, the result of this study would support the use 
of AR-targeted drugs as a potential therapeutic target for this 
subgroup [7,36]. This study shows that increased AR expression 
in TNBC was a marker of poor outcome and had a potential crosstalk link with the aggressiveness of this subgroup through 
increasing tumour dissociation and spread (tumour budding). 
AR-targeted drugs are effective therapeutic target for prostate 
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cancer and have been approved for treatment of castrate-
resistant prostate cancer [37]. Enzalutamide, a nonsteroidal 
inhibitor of nuclear localization of AR, was significantly improved 
overall survival in castrate-resistant prostate cancer [37,38]. 
Results from clinical trial examining the utility of 
enzalutamide in advanced TNBC has showed improved overall 
survival in patients with AR +ve tumours compared to those with 
AR -ve tumours, further suggesting AR as a potential therapeutic 
target in TNBC (clinicaltrials.gov: NCT01889238). In addition, a phase II trial of bicalutamide, an androgen antagonist, has 
shown a clinical benefit rate of 19% in a select group of patients 
with hormone receptor negative, AR positive breast cancer [39]. 
It has also shown that combining anti-androgens with a PI3K 
inhibitor increases their sensitivity in TNBC patients [40].In this study we also observed that in luminal A tumours 
increased AR expression leads to reduced CSS independent 
of other variables. This detrimental effect of AR on survival 
suggests that anti-androgen therapy may be of therapeutic 
benefit to patients with luminal disease. It was reported that 
when Tamoxifen-resistant breast cancer cells that expressed 
high levels of AR were exposed to bicalutamide (antiandrogen), cell growth was shown to decrease as well as reversing 
Tamoxifen resistance [41]. Therefore, antiandrogen treatment would be an effective therapeutic strategy for luminal cancers 
with Tamoxifen resistance. In addition, although not significant a 
trend was observed with better survival on AR positive Her2 like 
patients and therefore AR should not be targeted in this group.
In conclusion, this study shows unfavourable impacts of AR 
expression in breast cancer patients. In both luminal A (ER+ve) 
and TNBC (ER-ve), AR conveys a poor effect. This is potentially 
attributable to up-regulation of tumour budding within the 
tumour microenvironment. This suggests that AR may be an important regulator of tumour cells dissociation and migration 
in breast cancer. These data also suggest that AR is a potential 
prognostic biomarker for TNBC. Further investigation is now 
needed to define how AR is influencing tumour budding, is it a direct association or is another factor involved. 
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